Immunotherapy Approaches for Breast Cancer Patients in 2023

Emens, LA; Loi, S

Author(s): Emens, LA; Loi, S;
Details: Publication Year 2023-04-03,Volume 13,Issue #4,Page a041332
Journal Title: Cold Spring Harbor Perspectives in Medicine
Publication Type: Review
Abstract: Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis, harnesses the power of the immune system to treat cancer, with unique potential for a durable treatment effect due to immunologic memory. The PD-1 inhibitor pembrolizumab combined with neoadjuvant chemotherapy followed by adjuvant pembrolizumab improves event-free survival and is a new standard of care for high-risk, early-stage triple-negative breast cancer (TNBC), regardless of tumor PD-L1 expression. For metastatic TNBC, pembrolizumab combined with chemotherapy is a new standard of care for the first-line therapy of PD-L1(+) metastatic TNBC, with improvement in overall survival. The PD-L1 inhibitor atezolizumab combined with nab-paclitaxel is also approved outside the United States for the first-line treatment of metastatic PD-L1(+) TNBC. Current research focuses on refining the use of immunotherapy in TNBC by defining informative predictive biomarkers, developing immunotherapy in early and advanced HER2-driven and luminal breast cancers, and overcoming primary and secondary resistance to immunotherapy through unique immune-based strategies.
Publisher: Cold Spring Harbor Laboratory Press
Keywords: Humans; *Triple Negative Breast Neoplasms/drug therapy/metabolism; B7-H1 Antigen/therapeutic use; Biomarkers; Immunotherapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Department(s): Medical Oncology
PubMed ID: 37011999
Publisher's Version: https://doi.org/10.1101/cshperspect.a041332
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-07-19 07:47:31

Last Modified: 2023-07-19 07:47:59